Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation

Blood Advances
Monika Brüggemann, Michaela Kotrova

Abstract

Nowadays, minimal residual disease (MRD) is accepted as the strongest independent prognostic factor in acute lymphoblastic leukemia (ALL). It can be detected by molecular methods that use leukemia-specific or patient-specific molecular markers (fusion gene transcripts, or immunoglobulin/T-cell receptor [IG/TR] gene rearrangements), and by multi-parametric flow cytometry. The sensitivity and specificity of these methods can vary across treatment time points and therapeutic settings. Thus, knowledge of the principles and limitations of each technology is of the utmost importance for correct interpretation of MRD results. Time will tell whether new molecular and flow cytometric high-throughput technologies can overcome the limitations of current standard methods and eventually bring additional benefits. MRD during standard ALL chemotherapy is the strongest overall prognostic indicator and has therefore been used for refining initial treatment stratification. Moreover, MRD positivity after the maintenance phase of treatment may point to an impending relapse and thus enable salvage treatment to be initiated earlier, which could possibly improve treatment results. The prognostic relevance of pretransplantation MRD was shown by severa...Continue Reading

References

Oct 1, 2005·Blood·Monika BrüggemannUNKNOWN German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia
Oct 13, 2006·Blood·Adele K FieldingUNKNOWN Eastern Cooperative Oncology Group
Oct 7, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giuseppe BassoGiuseppe Gaipa
Oct 1, 2011·Blood Reviews·Dieter Hoelzer, Nicola Gökbuget
Feb 1, 2012·Seminars in Oncology·Monika BrüggemannMichael Kneba
Mar 24, 2012·Blood·Nicola GökbugetUNKNOWN German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia
Apr 12, 2012·Blood·Nicola GökbugetUNKNOWN German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia
May 4, 2012·Leukemia·J J M van DongenUNKNOWN EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708)
Sep 6, 2012·Leukemia·T KalinaUNKNOWN EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708)
Sep 11, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Aline Tanguy-SchmidtXavier Thomas
Oct 4, 2012·Blood·Monika BrüggemannMichael Kneba
Feb 21, 2014·Science Translational Medicine·Marco L DavilaRenier Brentjens
Apr 18, 2014·Blood·Kheira BeldjordUNKNOWN Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)
Jun 8, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Theis Helge TerweyRenate Arnold
Jul 23, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathryn G RobertsChing-Hon Pui
Sep 11, 2014·The New England Journal of Medicine·Kathryn G RobertsCharles G Mullighan
Nov 12, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Max S ToppRalf C Bargou
Apr 17, 2015·Blood·Yves ChalandonUNKNOWN Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)
May 23, 2015·European Journal of Haematology·Cyril ŠálekUNKNOWN Czech Leukemia Study Group - for Life (CELL)
Jul 2, 2015·Haematologica·Dieter Hoelzer
Jun 14, 2016·The New England Journal of Medicine·Hagop M KantarjianAnjali S Advani
Aug 6, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Federico LussanaAlessandro Rambaldi

❮ Previous
Next ❯

Citations

Mar 3, 2020·British Journal of Haematology·Yu AkahoshiUNKNOWN Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation
Feb 9, 2020·International Journal of Molecular Sciences·Aaron KruseYong-Mi Kim
Feb 20, 2020·Therapeutic Advances in Hematology·Francesca CarobolanteRenato Bassan
Nov 20, 2019·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Neha SinghAnurag Mehta
Jun 7, 2020·Journal of Hematology & Oncology·Bachar SamraNicholas J Short
Nov 18, 2018·Current Hematologic Malignancy Reports·Franklin Fuda, Weina Chen
Dec 7, 2019·Hematology·Jacqueline CloosRichard Dillon
Oct 6, 2020·Expert Review of Anticancer Therapy·Marie BalsatXavier Thomas
Jan 11, 2021·International Journal of Laboratory Hematology·Rodolfo P CorreiaNydia S Bacal
Sep 8, 2019·European Journal of Pharmacology·Akira Shimada
Feb 13, 2021·PLoS Computational Biology·Michael RaatzArne Traulsen
Nov 19, 2020·Critical Reviews in Clinical Laboratory Sciences·Nikolai LomovMikhail A Rubtsov
Mar 13, 2021·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Manisha AgarwalTathagata Chatterjee
Jun 8, 2021·Current Treatment Options in Oncology·Shukaib ArslanIbrahim Aldoss
Jul 27, 2021·Clinics in Laboratory Medicine·John Kim Choi, Paul E Mead

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.